Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Affimed N.V. AFMD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • DE • USD

SharesGrow Score
43/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.50
+4032.2%

Affimed N.V. (AFMD) is a Biotechnology company in the Healthcare sector, currently trading at $0.18. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is AFMD = $8 (+4032.2% upside).

Financials: revenue is $8M, -11.7%/yr average growth. Net income is $106M (loss), growing at -37.2%/yr. Net profit margin is -1280.2% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $19M against $58M equity (Debt-to-Equity (D/E) ratio 0.33, conservative). Current ratio is 3.25 (strong liquidity). Debt-to-assets is 19.9%. Total assets: $97M.

Analyst outlook: 6 / 11 analysts rate AFMD as buy (55%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$7.50
▲ 4032.23% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Affimed N.V., the average price target is $7.50, with a high forecast of $10.00, and a low forecast of $5.00.
Highest Price Target
$10.00
Average Price Target
$7.50
Lowest Price Target
$5.00

AFMD SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AFMD

✓
VALUE Pass
100/100
AFMD trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $8, implying +4307.7% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
AFMD: -11.7%/yr revenue is, -37.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet AFMD: Debt-to-Equity (D/E) ratio 0.33 (conservative), Current ratio is 3.25 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
AFMD: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 6 / 11 analysts rate AFMD as buy (55%). Analyst consensus target is $8 (+4307.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
AFMD: Net profit margin is -1280.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.018-8.95
Volume22.06M
Avg Volume (30D)15.65M
Market Cap$2.98M
Beta (1Y)2.07
Share Statistics
EPS (TTM)-7.09
Shares Outstanding$14.94M
IPO Date2014-09-12
Employees76
CEOShawn Leland
Financial Highlights & Ratios
Revenue (TTM)$8.28M
Gross Profit$8.28M
EBITDA$-102.38M
Net Income$-105.94M
Operating Income$-106.66M
Total Cash$72.9M
Total Debt$19.35M
Net Debt$-19.18M
Total Assets$97.16M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.36
Analyst Forecast
1Y Price Target$7.50
Target High$10.00
Target Low$5.00
Upside+4,032.2%
Rating ConsensusBuy
Analysts Covering11
Buy 55% Hold 45% Sell 0%
Price Target Summary
Company Info
CountryDE
ExchangeNASDAQ Global Market
CurrencyUSD
ISINNL0015001ZQ0

Price Chart

Track all markets on TradingView
AFMD
Affimed N.V. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.02 52WK RANGE 8.95

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.25
+0.53%
 ADCT
ADCT
ADC Therapeutics SA
$3.86
+1.31%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 AGEN
AGEN
Agenus Inc.
$4.72
+13.73%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message